Medpace Holdings, Inc. Investment Advisory Fees (Deprecated 2018-01-31)
Medpace Holdings, Inc. (MEDP) reported Investment Advisory Fees (Deprecated 2018-01-31) of $3.30 million for the 9-month period ending 2014-12-31, per its 10-K filed 2017-02-28.
Discontinued › Notes
us-gaap:InvestmentAdvisoryFees · last filed 2017-02-28
- 2014-12-31: Investment Advisory Fees (Deprecated 2018-01-31) 9 month $3.30M.
| Period end | Investment Advisory Fees (Deprecated 2018-01-31) 9 month |
|---|---|
| 2014-12-31 | $3.30M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |